⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ESPR News
Esperion Therapeutics, Inc.
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
ESPR
Form 8-K
sec.gov
ESPR
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
globenewswire.com
ESPR
KKR
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
businesswire.com
ESPR
KKR
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10
globenewswire.com
ESPR
Esperion to Participate in The 2026 Citizens Life Sciences Conference
globenewswire.com
ESPR
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
globenewswire.com
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
ESPR
Everspring Named a 2026 Best Places to Work for the Fifth Year as Company Accelerates AI Innovation in Higher Education
businesswire.com
ESPR
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight
globenewswire.com
AMGN
ARWR
IONS
NVS
NVO
MRK
LLY
REGN
ESPR
ALNY
VRTX
XBI